According to the agreement, Swedish Orphan Biovitrum will be dealing with the marketing and sales of Dongbao’s pipeline of biopharmaceuticals and other drugs in Europe. Whereas, Dongbao will be the marketing and sales partner of choice for Swedish Orphan Biovitrum’s marketed and pipeline products in China.
Further, Swedish Orphan Biovitrum is planning to deepen its collaboration with Dongbao, including its affiliate Rechon Life Science Group, for manufacturing services.
The current commercial alliance would be a partnership where both the entities are expected to benefit in two ways. First, each party secures a marketing and sales partner for its own products in China in the case of Swedish Orphan Biovitrum and Europe for Dongbao. Second, each party gains access to a new portfolio of exciting products for its home markets.
Swedish Orphan Biovitrum and Dongbao also intend to complete the first stage of the commercial alliance by completing ongoing negotiations regarding Iron Sucrose from Dongbao and Kineret from Swedish Orphan Biovitrum.
Martin Nicklasson, CEO of Swedish Orphan Biovitrum, said: “We are very pleased to have identified a partner in Dongbao with a successful track record of selling high value biotechnology products in China.
“Thus, we see Dongbao as the perfect partner to help Swedish Orphan Biovitrum to realize the significant opportunity for our products in the Chinese market. Additionally, we are excited about gaining access to Dongbao’s pipeline of high value Biosuperiors. We look forward to working with these products over the long term to realize the full commercial potential of these products in Europe.”
Zhaoqi Li, vice president of Dongbao Enterprise Group and chairman of the board of Rechon Life Science Group, said: “We admire Swedish Orphan Biovitrum’s remarkable efforts and achievements in the development of specialist pharmaceutical products for rare diseases.”